Bruno F. Marques

Dr. Bruno F. Marques

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2008 in Journal of Controlled Release
Verified
Journal Article
Closed access
LLLavinia Liguori
Lavinia Liguori
BMBruno F. Marques
Bruno F. Marques
AVAna Villegas-Mendez
Ana Villegas-Mendez
RRRomy Rothe
Romy Rothe
JLJean-Luc Lenormand
Jean-Luc Lenormand

7 April 2020 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
PDF file
JCJonathan Coffman
Jonathan Coffman
BMBruno F. Marques
Bruno F. Marques
RORaquel Orozco
Raquel Orozco
MAMinni Aswath
Minni Aswath
HMHasan Mohammad
Hasan Mohammad
Richard C. WillsonRichard C. Willson
Richard C. Willson

4 May 2023 in Biology
Verified
Journal Article
Open access
PDF file
CKChen-Yuan Kao
Chen-Yuan Kao
JMJason A. Mills
Jason A. Mills
CBCarl J. Burke
Carl J. Burke
BMBarry Morse
Barry Morse
BMBruno F. Marques
Bruno F. Marques
Cytokines and other growth factors are essential for cell expansion, health, function, and immune stimulation. Stem cells have the additional reliance on these factors to direct differentiation to the appropriate terminal cell type. Successful manufacturing of allogeneic cell therapies from induced pluripotent stem cells (iPSCs) requires close attention to the selection and control of cytokines and factors used throughout the manufacturing process, as well as after administration to the patient. This paper employs iPSC-derived natural killer cell/T cell therapeutics to illustrate the use of cytokines, growth factors, and transcription factors at different stages of the manufacturing process, ranging from the generation of iPSCs to controlling of iPSC differentiation into immune-effector cells through the support of cell therapy after patient administration.